If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00244712","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"true","masked_subject":"true","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"HEAT","allocation":"Randomized","arm_groups":[{"arm_group_label":"ABC/3TC","arm_group_description":"The intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo +lopinavir/ritonavir.","arm_type":"Experimental"},{"arm_group_label":"TDF/FTC","arm_group_description":"The intervention is a regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.","arm_type":"Active Comparator"}],"assignment":"Parallel Assignment","brief_summary":"This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA (lopinavir/ritonavir) over 96 weeks","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV Infection","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:03:58","criteria":"Inclusion criteria: - Males as females at least 18 years old. (A female is eligible to enter and participate in this study if she is of: non child-bearing potential, child bearing potential with a negative pregnancy test and agrees to approved contraception methods, or agreement for complete abstinence.) - Subject is antiretroviral-naïve (defined as having ≤14 days of prior therapy with any NRTI and no prior therapy with either a PI or NNRTI). - Subject has plasma HIV-1 RNA ≥ 1,000 copies/mL at screening. - Subject is willing and able to understand and provide written informed consent prior to participation in this study. Exclusion criteria: - Subject has an active or acute CDC Clinical Category C event (exclusive of cutaneous Kaposi's sarcoma) at screening. Treatment for the acute event must have been completed at least 30 days prior to screening. - Subject is enrolled in one or more investigational drug protocols, which may impact HIV-1 RNA suppression. - Subject is, in the opinion of the investigator, unable to complete the 96-week dosing period and protocol evaluations and assessments. - Subject is either pregnant or breastfeeding. - Subject has an ongoing clinically relevant pancreatitis or clinically relevant hepatitis at screening. - Subject suffers from a serious medical condition, such as cirrhosis, diabetes, congestive heart failure, cardiomyopathy or other cardiac dysfunction, which in the opinion of the investigator would compromise the safety of the subject. - Subject has a pre-existing mental, physical, or substance abuse disorder which, in the opinion of the investigator, may interfere with the subject's ability to comply with the dosing schedule and protocol evaluations and assessments. - Subject has a history of inflammatory bowel disease or malignancy, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction which may interfere with drug absorption or render the subject unable to take oral medication. - Subject has any acute laboratory abnormality at screening, which, in the opinion of the investigator, precludes the subject's participation in the study of an investigational compound. Any grade 4 laboratory abnormality will exclude a subject from study participation. - Subject has estimated creatinine clearance <50 mL/min via Cockroft-Gault method. - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN). - Subject has required treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to screening, or has an anticipated need for these agents within the study period. - Subject requires treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, vaccines, or interferons) within 28 days prior to Screen, or subject has received an HIV-1 immunotherapeutic vaccine within 90 days prior to Screen. Asthmatic subjects using inhaled corticosteroids are eligible for enrollment. - Subject requires treatment with foscarnet, hydroxyurea or other agents with documented activity against HIV-1 in vitro within 28 days of study administration. - Subjects who require treatment with the prohibited medications within 28 days of commencement of investigational product, or an anticipated need during the study. - Subject has a history of allergy to any of the study drugs or any excipients therein","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"688","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"aeb44927-f2fb-5f4c-9983-6740f241b555","internal":{"content":null,"contentDigest":"0a6e2be76d526df21b4ab36ec3220db8","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion criteria: - Males as females at least 18 years old. (A female is eligible to enter and participate in this study if she is of: non child-bearing potential, child bearing potential with a negative pregnancy test and agrees to approved contraception methods, or agreement for complete abstinence.) - Subject is antiretroviral-naïve (defined as having ≤14 days of prior therapy with any NRTI and no prior therapy with either a PI or NNRTI). - Subject has plasma HIV-1 RNA ≥ 1,000 copies/mL at screening. - Subject is willing and able to understand and provide written informed consent prior to participation in this study. Exclusion criteria: - Subject has an active or acute CDC Clinical Category C event (exclusive of cutaneous Kaposi's sarcoma) at screening. Treatment for the acute event must have been completed at least 30 days prior to screening. - Subject is enrolled in one or more investigational drug protocols, which may impact HIV-1 RNA suppression. - Subject is, in the opinion of the investigator, unable to complete the 96-week dosing period and protocol evaluations and assessments. - Subject is either pregnant or breastfeeding. - Subject has an ongoing clinically relevant pancreatitis or clinically relevant hepatitis at screening. - Subject suffers from a serious medical condition, such as cirrhosis, diabetes, congestive heart failure, cardiomyopathy or other cardiac dysfunction, which in the opinion of the investigator would compromise the safety of the subject. - Subject has a pre-existing mental, physical, or substance abuse disorder which, in the opinion of the investigator, may interfere with the subject's ability to comply with the dosing schedule and protocol evaluations and assessments. - Subject has a history of inflammatory bowel disease or malignancy, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction which may interfere with drug absorption or render the subject unable to take oral medication. - Subject has any acute laboratory abnormality at screening, which, in the opinion of the investigator, precludes the subject's participation in the study of an investigational compound. Any grade 4 laboratory abnormality will exclude a subject from study participation. - Subject has estimated creatinine clearance <50 mL/min via Cockroft-Gault method. - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN). - Subject has required treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to screening, or has an anticipated need for these agents within the study period. - Subject requires treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, vaccines, or interferons) within 28 days prior to Screen, or subject has received an HIV-1 immunotherapeutic vaccine within 90 days prior to Screen. Asthmatic subjects using inhaled corticosteroids are eligible for enrollment. - Subject requires treatment with foscarnet, hydroxyurea or other agents with documented activity against HIV-1 in vitro within 28 days of study administration. - Subjects who require treatment with the prohibited medications within 28 days of commencement of investigational product, or an anticipated need during the study. - Subject has a history of allergy to any of the study drugs or any excipients therein","interventions":[{"arm_group_label":"TDF/FTC","intervention_description":"The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.","intervention_name":"emtricitabine/tenofovir","intervention_type":"Drug"},{"arm_group_label":"ABC/3TC","intervention_description":"The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.","intervention_name":"abacavir/lamivudine","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["HEAT","Antiretroviral-naive","HIV","EPZICOM","TRUVADA","KALETRA","once-daily"],"last_follow_up_date":"04/01/2008 00:00:00","links":[],"locations":[{"City":"Atlanta","Latitude":"33.776402","CountryDisplay":"United States","Longitude":"-84.38926","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30308/30309","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"West Reading","Latitude":"40.3337038","CountryDisplay":"United States","Longitude":"-75.9474322","Name":"GSK Investigational Site","StateDisplay":"Pennsylvania","PostalCode":"19611","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7464969","CountryDisplay":"United States","Longitude":"-74.0094471","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10011","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7645239","CountryDisplay":"United States","Longitude":"-73.9624327","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10065","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami","Latitude":"25.7870967","CountryDisplay":"United States","Longitude":"-80.2042436","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33136","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Houston","Latitude":"29.7050857","CountryDisplay":"United States","Longitude":"-95.4018087","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77030","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Oakland","Latitude":"37.8321173","CountryDisplay":"United States","Longitude":"-122.2625529","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94609","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7962048","CountryDisplay":"United States","Longitude":"-96.7694752","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75246","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chicago","Latitude":"41.9403795","CountryDisplay":"United States","Longitude":"-87.6531805","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60657","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Norwalk","Latitude":"41.1339818","CountryDisplay":"United States","Longitude":"-73.4062342","Name":"GSK Investigational Site","StateDisplay":"Connecticut","PostalCode":"06851","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tyler","Latitude":"32.4073961","CountryDisplay":"United States","Longitude":"-95.2057909","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75708","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"26.1640451","CountryDisplay":"United States","Longitude":"-80.1121493","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33306","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Key West","Latitude":"24.5550593","CountryDisplay":"United States","Longitude":"-81.7799871","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33040","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Las Vegas","Latitude":"36.1462673","CountryDisplay":"United States","Longitude":"-115.1829873","Name":"GSK Investigational Site","StateDisplay":"Nevada","PostalCode":"89102","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fountain Valley","Latitude":"33.7168761","CountryDisplay":"United States","Longitude":"-117.9600466","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92708","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Portland","Latitude":"45.4618086","CountryDisplay":"United States","Longitude":"-122.7181903","Name":"GSK Investigational Site","StateDisplay":"Oregon","PostalCode":"97219","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Greenville","Latitude":"35.612661","CountryDisplay":"United States","Longitude":"-77.3663538","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"27834","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Rochester","Latitude":"43.1581207","CountryDisplay":"United States","Longitude":"-77.6063541","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"14604","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Charlotte","Latitude":"35.1811188","CountryDisplay":"United States","Longitude":"-80.8488498","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"28209","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Garden Grove","Latitude":"33.7852683","CountryDisplay":"United States","Longitude":"-118.0273914","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92845","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"26.1897731","CountryDisplay":"United States","Longitude":"-80.1037721","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33308","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Baltimore","Latitude":"39.2963369","CountryDisplay":"United States","Longitude":"-76.6210539","Name":"GSK Investigational Site","StateDisplay":"Maryland","PostalCode":"21201","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Denver","Latitude":"39.7558119","CountryDisplay":"United States","Longitude":"-104.9680914","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80205","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Phoenix","Latitude":"33.4636012","CountryDisplay":"United States","Longitude":"-112.0535987","Name":"GSK Investigational Site","StateDisplay":"Arizona","PostalCode":"85006","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tampa","Latitude":"27.9552692","CountryDisplay":"United States","Longitude":"-82.4563199","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33602","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Augusta","Latitude":"33.4706725","CountryDisplay":"United States","Longitude":"-81.9861463","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30912","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"St. Louis","Latitude":"38.647459","CountryDisplay":"United States","Longitude":"-90.25731","Name":"GSK Investigational Site","StateDisplay":"Missouri","PostalCode":"63108","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Washington","Latitude":"38.9191485","CountryDisplay":"United States","Longitude":"-77.0362967","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20009","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Long Beach","Latitude":"33.7844997","CountryDisplay":"United States","Longitude":"-118.1971031","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90813","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Myers","Latitude":"26.6235485","CountryDisplay":"United States","Longitude":"-81.8770671","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33901","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Longview","Latitude":"32.502529","CountryDisplay":"United States","Longitude":"-94.8002333","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75604","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ponce","Latitude":"18.1311468","CountryDisplay":"Puerto Rico","Longitude":"-66.6395219","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"00731","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Washington","Latitude":"38.9042365","CountryDisplay":"United States","Longitude":"-77.0521289","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20037","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.7717008","CountryDisplay":"United States","Longitude":"-84.3726049","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30308","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Charlottesville","Latitude":"38.0318885","CountryDisplay":"United States","Longitude":"-78.4984804","Name":"GSK Investigational Site","StateDisplay":"Virginia","PostalCode":"22908","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.8676889","CountryDisplay":"United States","Longitude":"-84.4645184","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30339","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tampa","Latitude":"28.0133862","CountryDisplay":"United States","Longitude":"-82.5077593","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33614","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Denver","Latitude":"39.7316982","CountryDisplay":"United States","Longitude":"-104.9213643","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80220","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Maywood","Latitude":"41.8791979","CountryDisplay":"United States","Longitude":"-87.8431155","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60153","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lynchburg","Latitude":"37.4137536","CountryDisplay":"United States","Longitude":"-79.1422464","Name":"GSK Investigational Site","StateDisplay":"Virginia","PostalCode":"24501","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Philadelphia","Latitude":"40.012545","CountryDisplay":"United States","Longitude":"-75.1487007","Name":"GSK Investigational Site","StateDisplay":"Pennsylvania","PostalCode":"19140","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Phoenix","Latitude":"33.5114334","CountryDisplay":"United States","Longitude":"-112.0685027","Name":"GSK Investigational Site","StateDisplay":"Arizona","PostalCode":"85012","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chicago","Latitude":"41.8816606","CountryDisplay":"United States","Longitude":"-87.6926257","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60612","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chicago","Latitude":"41.7805099","CountryDisplay":"United States","Longitude":"-87.603826","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60637","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.0931603","CountryDisplay":"United States","Longitude":"-118.3783347","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90069","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Somers Point","Latitude":"39.3140235","CountryDisplay":"United States","Longitude":"-74.5990492","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"08244","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Oakland","Latitude":"37.8015517","CountryDisplay":"United States","Longitude":"-122.2143323","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94602","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Washington","Latitude":"38.9156487","CountryDisplay":"United States","Longitude":"-77.0737149","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20007","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tucson","Latitude":"32.2625656","CountryDisplay":"United States","Longitude":"-111.1175767","Name":"GSK Investigational Site","StateDisplay":"Arizona","PostalCode":"85745","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Decatur","Latitude":"33.8092255","CountryDisplay":"United States","Longitude":"-84.2805478","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30033","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"26.0977657","CountryDisplay":"United States","Longitude":"-80.1261093","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33316","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Austin","Latitude":"30.3055711","CountryDisplay":"United States","Longitude":"-97.725376","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"78751","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Columbia","Latitude":"34.0258687","CountryDisplay":"United States","Longitude":"-80.9594751","Name":"GSK Investigational Site","StateDisplay":"South Carolina","PostalCode":"29206","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Annandale","Latitude":"38.8327423","CountryDisplay":"United States","Longitude":"-77.2060241","Name":"GSK Investigational Site","StateDisplay":"Virginia","PostalCode":"22003","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sarasota","Latitude":"27.3086034","CountryDisplay":"United States","Longitude":"-82.5239953","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"34239","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hillsborough","Latitude":"40.5106594","CountryDisplay":"United States","Longitude":"-74.6472522","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"08844","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Plantation","Latitude":"26.1218038","CountryDisplay":"United States","Longitude":"-80.2209773","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33317","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Glastonbury","Latitude":"41.7056381","CountryDisplay":"United States","Longitude":"-72.5559746","Name":"GSK Investigational Site","StateDisplay":"Connecticut","PostalCode":"06033","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7457134","CountryDisplay":"United States","Longitude":"-96.8458204","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75208","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lexington","Latitude":"38.0327247","CountryDisplay":"United States","Longitude":"-84.5066144","Name":"GSK Investigational Site","StateDisplay":"Kentucky","PostalCode":"40536","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Newport Beach","Latitude":"33.615828","CountryDisplay":"United States","Longitude":"-117.9307584","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92663","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Port St. Lucie","Latitude":"27.2932971","CountryDisplay":"United States","Longitude":"-80.2878794","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"34952","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Denver","Latitude":"39.7380371","CountryDisplay":"United States","Longitude":"-105.0265195","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80204","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Worth","Latitude":"32.7248887","CountryDisplay":"United States","Longitude":"-97.3138554","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"76104","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Toledo","Latitude":"41.5993157","CountryDisplay":"United States","Longitude":"-83.6295222","Name":"GSK Investigational Site","StateDisplay":"Ohio","PostalCode":"43614","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Milwaukee","Latitude":"43.0513426","CountryDisplay":"United States","Longitude":"-88.0411993","Name":"GSK Investigational Site","StateDisplay":"Wisconsin","PostalCode":"53226","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Harlingen","Latitude":"26.2625297","CountryDisplay":"United States","Longitude":"-97.654811","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"78550","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sarasota","Latitude":"27.4081935","CountryDisplay":"United States","Longitude":"-82.5294065","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"34243","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hampton","Latitude":"37.0538822","CountryDisplay":"United States","Longitude":"-76.3984537","Name":"GSK Investigational Site","StateDisplay":"Virginia","PostalCode":"23666","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Louisville","Latitude":"38.2556928","CountryDisplay":"United States","Longitude":"-85.751283","Name":"GSK Investigational Site","StateDisplay":"Kentucky","PostalCode":"40202","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Beverly Hills","Latitude":"34.1030032","CountryDisplay":"United States","Longitude":"-118.4104684","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90210","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Juan","Latitude":"18.4465407","CountryDisplay":"Puerto Rico","Longitude":"-66.067938","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"00909-1711","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Newark","Latitude":"40.7350747","CountryDisplay":"United States","Longitude":"-74.1739057","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"07102","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Houston","Latitude":"29.740582","CountryDisplay":"United States","Longitude":"-95.4515725","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77027","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Double Blind","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 23:04:17","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination with KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects","org_study_id":"EPZ104057","overall_contact":{"email":null,"last_name":"US GSK Clinical Trials Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 4","primary_compl_date":"04/01/2008 00:00:00","primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"EPZ104057","id_type":"","id_domain":""}],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"07/01/2005 00:00:00","study_type":"interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":true}},"pageContext":{"studyId":"EPZ104057"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}